- Home
- CYCU vs APRE Comparison
CYCU vs APRE Comparison
Compare CYCU & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CYCU | APRE |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 6.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CYCU | APRE |
|---|---|---|
| Price | $1.68 | $0.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | $5.50 |
| AVG Volume (30 Days) | 174.4K | ★ 6.0M |
| Earning Date | 04-17-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,667,874.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.62 | $0.55 |
| 52 Week High | $892.86 | $3.72 |
Technical Indicators
Market Signals| Indicator | CYCU | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 31.20 | 36.45 |
| Support Level | $1.71 | $0.58 |
| Resistance Level | $2.18 | $0.69 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 19.55 | 6.78 |
Price Performance
Historical ComparisonAbout CYCU Cycurion Inc.
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.